18F-Sodium fluoride positron emission tomography: History, technical feasibility, mechanism of action, normal bio-distribution, and diagnostic performance in bone metastasis detection compared to other imaging modalities.

The skeleton is overall the third most common metastatic site after the lungs and liver. Accurate diagnosis of osseous metastasis is critical for initial staging, treatment planning, restaging, treatment monitoring and survival prediction. Currently, 99mTc-methylene diphosphonate (99mTc-MDP) whole-body scan is the cornerstone of imaging to detect osseous metastasis. Though 18F-sodium fluoride (18F-NaF) was one of the oldest medical tracers but was replaced by other tracers until recently, owing to its physical properties. Continued development of positron emission tomographic (PET) scanners have opened a new era for 18F-NaF and given its higher sensitivity, there have been increasing applications in imaging. In this review, we will discuss the history, technical aspects, radiobiology, and bio-distribution of this tracer. Finally, we compared the accuracy of 18F-NaF PET with other conventional imaging for detection of osseous metastasis.

[1]  H. Zacho,et al.  No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy , 2019, The Journal of Nuclear Medicine.

[2]  Yue Chen,et al.  Comparison of 18F-NaF PET/CT and 18F-FDG PET/CT for Detection of Skull-Base Invasion and Osseous Metastases in Nasopharyngeal Carcinoma , 2018, Contrast media & molecular imaging.

[3]  Nagabhushan Seshadri,et al.  Skeletal Metastases and Benign Mimics on NaF PET/CT: A Pictorial Review. , 2018, AJR. American journal of roentgenology.

[4]  F. Mottaghy,et al.  Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  B. Chatterton,et al.  18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer , 2017, Prostate international.

[6]  Giuseppe Esposito,et al.  Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease , 2017, The Journal of Nuclear Medicine.

[7]  Lucy Hanna,et al.  Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry , 2017, The Journal of Nuclear Medicine.

[8]  N. Gupta,et al.  Usefulness of Radium-223 in Patients with Bone Metastases , 2017, Proceedings.

[9]  P. Hogg,et al.  The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer , 2016, The Journal of Nuclear Medicine Technology.

[10]  P. Choyke,et al.  Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[11]  Valentina Taviani,et al.  Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[12]  G. Aras,et al.  The role of 18F–NaF PET/CT in metastatic bone disease , 2015, Journal of bone oncology.

[13]  F. Mottaghy,et al.  18F-NaF PET/CT: EANM procedure guidelines for bone imaging , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Lucy Hanna,et al.  18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry , 2015, The Journal of Nuclear Medicine.

[15]  Quan-Yong Luo,et al.  Performance of 18F-Fluoride PET or PET/CT for the Detection of Bone Metastases: A Meta-analysis , 2015, Clinical nuclear medicine.

[16]  R. Jeraj,et al.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. , 2015, American journal of nuclear medicine and molecular imaging.

[17]  M. H. Poulsen,et al.  Spine metastases in prostate cancer: comparison of technetium‐99m‐MDP whole‐body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT , 2014, BJU international.

[18]  David S W Djang,et al.  Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[19]  M. Perry,et al.  Molecular imaging in oncology: (18)F-sodium fluoride PET imaging of osseous metastatic disease. , 2014, AJR. American journal of roentgenology.

[20]  R. Coleman,et al.  Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.

[21]  R. Coleman,et al.  Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.

[22]  G. Segall PET/CT with Sodium 18F-Fluoride for Management of Patients with Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[23]  D. Hose,et al.  PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  F. M. van der Zant,et al.  A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer , 2013, Nuclear medicine communications.

[25]  D. Chakraborty,et al.  Comparison of 18F Fluoride PET/CT and 99mTc-MDP Bone Scan in the Detection of Skeletal Metastases in Urinary Bladder Carcinoma , 2013, Clinical nuclear medicine.

[26]  R. Herfkens,et al.  Pilot Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases , 2013, Clinical nuclear medicine.

[27]  U. Tateishi,et al.  Assessment of atherosclerosis in oncologic patients using 18F-fluoride PET/CT , 2013, Annals of Nuclear Medicine.

[28]  Lalit Kumar,et al.  The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan , 2013, Japanese Journal of Radiology.

[29]  G. Cook Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial , 2013, The Journal of Nuclear Medicine.

[30]  T. Ohlsson,et al.  Combined 18F‐fluorocholine and 18F‐fluoride positron emission tomography/computed tomography imaging for staging of high‐risk prostate cancer , 2012, BJU international.

[31]  T. Yen,et al.  Utility of 18F-Fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-Risk Head and Neck Cancer Patients , 2012, The Journal of Nuclear Medicine.

[32]  C. Ramos,et al.  18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  S. Groshen,et al.  Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer , 2012, Clinical nuclear medicine.

[34]  E. Mittra,et al.  Prospective Evaluation of 99mTc MDP Scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for Detection of Skeletal Metastases , 2012, Molecular Imaging and Biology.

[35]  O. Cussenot,et al.  Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[36]  Sue Chua,et al.  18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) , 2011, EJNMMI research.

[37]  Nagichettiar Satyamurthy,et al.  Molecular Mechanisms of Bone 18F-NaF Deposition , 2010, The Journal of Nuclear Medicine.

[38]  Michael G. Stabin,et al.  SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0* , 2010, The Journal of Nuclear Medicine.

[39]  U. Tateishi,et al.  A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor , 2010, Annals of nuclear medicine.

[40]  Yen-Wen Wu,et al.  The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients , 2010, Nuclear medicine communications.

[41]  U. Tateishi,et al.  18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT , 2010, Annals of nuclear medicine.

[42]  Christian Schumann,et al.  Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  E. Mittra,et al.  Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.

[44]  P. Waldenberger,et al.  Assessment of malignant and benign bone lesions by static F-18 Fluoride PET-CT: Additional value of SUV! , 2008 .

[45]  S Ted Treves,et al.  Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer* , 2007, Journal of Nuclear Medicine.

[46]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  Eyal Mishani,et al.  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  H. Schirrmeister,et al.  F‐18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost‐Effectiveness, and Impact on Patient Management , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  H. Schirrmeister,et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  G. Blake,et al.  Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics , 2001, Nuclear medicine communications.

[51]  H. Schirrmeister,et al.  Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. , 2001, Thyroid : official journal of the American Thyroid Association.

[52]  I. Fogelman,et al.  Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[53]  J Kotzerke,et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Bergh,et al.  Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT , 1998, Skeletal Radiology.

[56]  P. Kantoff,et al.  (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. , 2015, American journal of nuclear medicine and molecular imaging.